Rothschild Investment Corp IL lessened its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 1.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,857 shares of the biopharmaceutical company’s stock after selling 1,185 shares during the quarter. Rothschild Investment Corp IL’s holdings in Bristol-Myers Squibb were worth $3,796,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Hammer Asset Management LLC raised its position in shares of Bristol-Myers Squibb by 9.5% during the 1st quarter. Hammer Asset Management LLC now owns 40,698 shares of the biopharmaceutical company’s stock valued at $1,942,000 after buying an additional 3,525 shares in the last quarter. Perella Weinberg Partners Capital Management LP raised its position in shares of Bristol-Myers Squibb by 10.9% during the 1st quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 1,905 shares in the last quarter. REDW Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $224,000. Kahn Brothers Group Inc. DE raised its position in shares of Bristol-Myers Squibb by 2,428.1% during the 1st quarter. Kahn Brothers Group Inc. DE now owns 504,350 shares of the biopharmaceutical company’s stock valued at $24,063,000 after buying an additional 484,400 shares in the last quarter. Finally, Towerview LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $477,000. 80.17% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have recently issued reports on BMY. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research report on Thursday, June 13th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Wednesday, August 14th. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Bank of America upped their target price on shares of Bristol-Myers Squibb from $49.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $55.81.
Bristol-Myers Squibb stock traded up $0.82 during midday trading on Friday, reaching $51.60. The stock had a trading volume of 966,428 shares, compared to its average volume of 9,791,409. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $60.77. The firm has a market cap of $82.38 billion, a price-to-earnings ratio of 12.97, a price-to-earnings-growth ratio of 2.48 and a beta of 0.72. The company has a fifty day moving average of $49.24 and a 200 day moving average of $47.03.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the company posted $1.01 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.29 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Gross Domestic Product (GDP)
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.